Literature DB >> 22752463

Impact of menopausal status on background parenchymal enhancement and fibroglandular tissue on breast MRI.

Valencia King1, Yajia Gu, Jennifer B Kaplan, Jennifer D Brooks, Malcolm C Pike, Elizabeth A Morris.   

Abstract

OBJECTIVE: To evaluate the effect of menopausal status on the background parenchymal enhancement (BPE) and amount of fibroglandular tissue (FGT) on breast MRI.
METHODS: Retrospective review identified 1,130 women who underwent screening breast MRI between July and November 2010. In 28 of these women, breast MRI was performed both at one time point while pre- and one time point while post-menopausal (median interval 49 months). Two independent readers blinded to menopausal status used categorical scales to rate BPE (minimal/mild/moderate/marked) and FGT (fatty/scattered/heterogeneously dense/dense). Consensus was reached when there was disagreement. The sign test was used to assess changes in rating categories, and the Spearman rank and Fisher's exact tests were used to measure correlations and associations between variables.
RESULTS: Significant proportions of women demonstrated decreases in BPE and FGT on post-menopausal breast MRI (P = 0.0001 and P = 0.0009). BPE category was unchanged in 39 % (11/28) and decreased in 61 % (17/28) of women. FGT category was unchanged in 61 % (17/28) and decreased in 39 % (11/28) of women. Age, reason for menopause, or interval between MRIs had no significant impact on changes in BPE and FGT.
CONCLUSION: On MRI, BPE, and FGT decrease after menopause in significant proportions of women; BPE decreases more than FGT. KEY POINTS: On MRI, background parenchymal enhancement and fibroglandular tissue both decrease after menopause. The reduced postmenopausal enhancement is more marked in parenchyma than fibroglandular tissue. Background enhancement and fibroglandular tissue seen on MRI are under hormonal influence.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22752463     DOI: 10.1007/s00330-012-2553-8

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  14 in total

1.  A longitudinal study of the effects of menopause on mammographic features.

Authors:  Norman Boyd; Lisa Martin; Jennifer Stone; Laurie Little; Salomon Minkin; Martin Yaffe
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2002-10       Impact factor: 4.254

2.  Background parenchymal enhancement at breast MR imaging and breast cancer risk.

Authors:  Valencia King; Jennifer D Brooks; Jonine L Bernstein; Anne S Reiner; Malcolm C Pike; Elizabeth A Morris
Journal:  Radiology       Date:  2011-04-14       Impact factor: 11.105

Review 3.  Diagnostic breast MR imaging: current status and future directions.

Authors:  Elizabeth A Morris
Journal:  Radiol Clin North Am       Date:  2007-09       Impact factor: 2.303

4.  Hormone replacement therapy in postmenopausal women: breast tissue perfusion determined with MR imaging--initial observations.

Authors:  Jean-Paul Delille; Priscilla J Slanetz; Eren D Yeh; Daniel B Kopans; Elkan F Halpern; Leoncio Garrido
Journal:  Radiology       Date:  2005-04       Impact factor: 11.105

5.  The measurement of observer agreement for categorical data.

Authors:  J R Landis; G G Koch
Journal:  Biometrics       Date:  1977-03       Impact factor: 2.571

6.  Background parenchymal enhancement on baseline screening breast MRI: impact on biopsy rate and short-interval follow-up.

Authors:  Niamh M Hambly; Laura Liberman; D David Dershaw; Sandra Brennan; Elizabeth A Morris
Journal:  AJR Am J Roentgenol       Date:  2011-01       Impact factor: 3.959

7.  Normal parenchymal enhancement patterns in women undergoing MR screening of the breast.

Authors:  Sanaz A Jansen; Vicky C Lin; Maryellen L Giger; Hui Li; Gregory S Karczmar; Gillian M Newstead
Journal:  Eur Radiol       Date:  2011-02-17       Impact factor: 5.315

8.  Menstrual cycle and age: influence on parenchymal contrast medium enhancement in MR imaging of the breast.

Authors:  M Müller-Schimpfle; K Ohmenhaüser; P Stoll; K Dietz; C D Claussen
Journal:  Radiology       Date:  1997-04       Impact factor: 11.105

9.  Breast magnetic resonance imaging findings in women treated with toremifene for premenstrual mastalgia.

Authors:  S Oksa; R Parkkola; T Luukkaala; J Mäenpää
Journal:  Acta Radiol       Date:  2009-11       Impact factor: 1.990

10.  Changes in magnetic resonance mammography due to hormone replacement therapy.

Authors:  Stefan O R Pfleiderer; Steffen Sachse; Dieter Sauner; Christiane Marx; Ansgar Malich; Susanne Wurdinger; Werner A Kaiser
Journal:  Breast Cancer Res       Date:  2004-03-16       Impact factor: 6.466

View more
  39 in total

1.  Mammographic density, MRI background parenchymal enhancement and breast cancer risk.

Authors:  M C Pike; C L Pearce
Journal:  Ann Oncol       Date:  2013-11       Impact factor: 32.976

2.  Evaluation of the kinetic properties of background parenchymal enhancement throughout the phases of the menstrual cycle.

Authors:  Alana R Amarosa; Jason McKellop; Ana Paula Klautau Leite; Melanie Moccaldi; Tess V Clendenen; James S Babb; Anne Zeleniuch-Jacquotte; Linda Moy; Sungheon Kim
Journal:  Radiology       Date:  2013-05-08       Impact factor: 11.105

Review 3.  Evaluation of background parenchymal enhancement on breast MRI: a systematic review.

Authors:  Bianca Bignotti; Alessio Signori; Francesca Valdora; Federica Rossi; Massimo Calabrese; Manuela Durando; Giovanna Mariscotto; Alberto Tagliafico
Journal:  Br J Radiol       Date:  2016-12-07       Impact factor: 3.039

4.  Dose-response effects of aerobic exercise on estrogen among women at high risk for breast cancer: a randomized controlled trial.

Authors:  Kathryn H Schmitz; Nancy I Williams; Despina Kontos; Susan Domchek; Knashawn H Morales; Wei-Ting Hwang; Lorita L Grant; Laura DiGiovanni; Domenick Salvatore; Desire' Fenderson; Mitchell Schnall; Mary Lou Galantino; Jill Stopfer; Mindy S Kurzer; Shandong Wu; Jessica Adelman; Justin C Brown; Jerene Good
Journal:  Breast Cancer Res Treat       Date:  2015-10-28       Impact factor: 4.872

5.  Comparison of Background Parenchymal Enhancement at Contrast-enhanced Spectral Mammography and Breast MR Imaging.

Authors:  Julie Sogani; Elizabeth A Morris; Jennifer B Kaplan; Donna D'Alessio; Debra Goldman; Chaya S Moskowitz; Maxine S Jochelson
Journal:  Radiology       Date:  2016-07-04       Impact factor: 11.105

6.  The relationship of breast density in mammography and magnetic resonance imaging in high-risk women and women with breast cancer.

Authors:  Marissa Albert; Freya Schnabel; Jennifer Chun; Shira Schwartz; Jiyon Lee; Ana Paula Klautau Leite; Linda Moy
Journal:  Clin Imaging       Date:  2015-08-06       Impact factor: 1.605

7.  Background parenchymal enhancement in breast MRI before and after neoadjuvant chemotherapy: correlation with tumour response.

Authors:  H Preibsch; L Wanner; S D Bahrs; B M Wietek; K C Siegmann-Luz; E Oberlecher; M Hahn; A Staebler; K Nikolaou; B Wiesinger
Journal:  Eur Radiol       Date:  2015-09-17       Impact factor: 5.315

8.  High-background parenchymal enhancement in the contralateral breast is an imaging biomarker for favorable prognosis in patients with triple-negative breast cancer treated with chemotherapy.

Authors:  Chuanhui Xu; Jinhui Yu; Feifei Wu; Xuemei Li; Dongmin Hu; Guiming Chen; Gang Wu
Journal:  Am J Transl Res       Date:  2021-05-15       Impact factor: 4.060

9.  Assessment of Background Parenchymal Enhancement and Lesion Kinetics in Breast MRI of BRCA 1/2 Mutation Carriers Compared to Matched Controls Using Quantitative Kinetic Analysis.

Authors:  Alana A Lewin; Sungheon Gene Kim; James S Babb; Amy N Melsaether; Jason McKellop; Melanie Moccaldi; Ana Paula Klautau Leite; Linda Moy
Journal:  Acad Radiol       Date:  2016-01-07       Impact factor: 3.173

10.  Background 99mTc-methoxyisobutylisonitrile uptake of breast-specific gamma imaging in relation to background parenchymal enhancement in magnetic resonance imaging.

Authors:  Hai-Jeon Yoon; Yemi Kim; Jee Eun Lee; Bom Sahn Kim
Journal:  Eur Radiol       Date:  2014-09-13       Impact factor: 5.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.